Compare Moderna, Inc. (MRNA) vs Southern Copper Corp (SCCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Southern Copper Corp — how do they compare? Moderna, Inc. trades at $63.68 (market cap $24.18B), while Southern Copper Corp trades at $195 (market cap $164.21B). The key difference: Southern Copper Corp is far larger — about 6.8× Moderna, Inc.'s market cap, and Southern Copper Corp pays a 2.26% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | SCCO | |
|---|---|---|
Market Cap | $24.18B | $164.21B |
Sector | Health | Basic Materials |
52-Week High | $81.80 | $218.85 |
52-Week Low | $22.36 | $93.70 |
Enterprise Value | $20.33B | $165.50B |
Dividend Yield | — | 2.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
Southern Copper (SCCO) trades at $194.86, down 2.62% on the day, with a bullish technical signal from moving averages and strong support at $191. The company reported record Q2 2026 earnings, beating estimates with EPS of $1.99, driven by high metal prices, though production volumes declined. Revenue and net income have grown consistently, with 2025 revenue at $13.42B and net income at $4.33B, reflecting a net margin of 35.87%.
Outlook remains positive due to robust profitability and AI-driven copper demand, but risks include premium valuation (P/E 29.18), reliance on metal prices, and mixed analyst sentiment with a consensus price target of $153.64 below current levels. Institutional buying and strong cash flow trends support growth, yet investors face volatility from commodity cycles and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →
